Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Unknown 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2

Conditions

Myelodysplastic Syndromes 1478Leukemia, Myeloid, Acute 1239Leukemia, Myelogenous, Chronic, BCR-ABL Positive 863Leukemia 745Precursor Cell Lymphoblastic Leukemia-Lymphoma 704Myeloproliferative Disorders 631Leukemia, Myelomonocytic, Chronic 455Lymphoma, Non-Hodgkin 447Primary Myelofibrosis 430Multiple Myeloma 423Leukemia, Lymphocytic, Chronic, B-Cell 408Hodgkin Disease 384Lymphoma 343Leukemia, Myeloid, Chronic-Phase 335Blast Crisis 282Polycythemia Vera 267Leukemia, Myeloid, Accelerated Phase 263Lymphoma, Follicular 254Lymphoma, Mantle-Cell 253Burkitt Lymphoma 246Lymphoma, Large B-Cell, Diffuse 244Lymphoma, B-Cell, Marginal Zone 225Congenital Abnormalities 215Lymphoma, Large-Cell, Immunoblastic 201Myelodysplastic-Myeloproliferative Diseases 199Thrombocythemia, Essential 197Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 196Anemia, Refractory, with Excess of Blasts 194Hematologic Neoplasms 193Neoplasms, Plasma Cell 184

Interventions

masitinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Blushing × Myeloid × Clear all
NCT04333108 2023-05-06

Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment

AB Science

Phase 3 Unknown
140 enrolled
Myeloid

Blushing, Mastocytosis, Pruritus, Piebaldism, Mastocytosis, Systemic

NCT00814073 2019-12-03

AB06006

AB Science

Phase 3 Completed
135 enrolled
Myeloid

Blushing, Mastocytosis, Pruritus, Piebaldism, Mastocytosis, Systemic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡